Wanbury Limited Market Cap ($72.70 Million)
Market Cap & Net Worth: Wanbury Limited (WANBURY)
Wanbury Limited market cap. Wanbury Limited (NSE:WANBURY) has a market capitalization of $72.70 Million (Rs6.72 Billion) as of November 5, 2026. Listed on the NSE stock exchange, this India-based company holds position #20267 globally and #1117 in its home market, demonstrating a 9.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wanbury Limited's stock price Rs192.41 by its total outstanding shares 34939398 (34.94 Million). Also see WANBURY operating cash flow for how efficiently the company converts equity into cash flow.
Wanbury Limited Market Cap History (2015–2026)
Wanbury Limited market cap history from 2015 to 2026. Data shows growth from $34.74 Million to $72.70 Million (10.23% CAGR). Check Wanbury Limited (WANBURY) stock price for real-time trading data and today's change.
Wanbury Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wanbury Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore WANBURY net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.01x
Wanbury Limited's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.28x
Wanbury Limited's market cap is 0.28 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $23.28 Million | $4.23 Billion | -$71.46 Million | 0.01x | N/A |
| 2017 | $16.78 Million | $4.29 Billion | $620.15 Million | 0.00x | 0.03x |
| 2018 | $7.69 Million | $3.68 Billion | -$320.08 Million | 0.00x | N/A |
| 2019 | $7.03 Million | $3.87 Billion | -$248.48 Million | 0.00x | N/A |
| 2020 | $17.63 Million | $3.63 Billion | $644.62 Million | 0.00x | 0.03x |
| 2021 | $31.87 Million | $3.87 Billion | -$126.06 Million | 0.01x | N/A |
| 2022 | $18.51 Million | $5.11 Billion | $814.74 Million | 0.00x | 0.02x |
| 2023 | $47.63 Million | $4.98 Billion | -$103.96 Million | 0.01x | N/A |
| 2024 | $110.02 Million | $5.74 Billion | $559.56 Million | 0.02x | 0.20x |
| 2025 | $85.62 Million | $6.00 Billion | $305.30 Million | 0.01x | 0.28x |
Competitor Companies of WANBURY by Market Capitalization
Companies near Wanbury Limited in the global market cap rankings as of November 5, 2026. Also see Wanbury Limited asset portfolio for a full breakdown of the balance sheet.
Key companies related to Wanbury Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Wanbury Limited (2015–2026)
Market capitalization of Wanbury Limited from 2015 to today. Between 2015 and today, Wanbury Limited's market cap moved from $34.74 Million to $ 72.70 Million, with a yearly change of 10.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs72.70 Million | -15.09% |
| 2025 | Rs85.62 Million | -22.18% |
| 2024 | Rs110.02 Million | +131.00% |
| 2023 | Rs47.63 Million | +157.24% |
| 2022 | Rs18.51 Million | -41.91% |
| 2021 | Rs31.87 Million | +80.81% |
| 2020 | Rs17.63 Million | +150.81% |
| 2019 | Rs7.03 Million | -8.60% |
| 2018 | Rs7.69 Million | -54.17% |
| 2017 | Rs16.78 Million | -27.92% |
| 2016 | Rs23.28 Million | -33.01% |
| 2015 | Rs34.74 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Wanbury Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $72.70 Million USD |
| MoneyControl | $72.70 Million USD |
| MarketWatch | $72.70 Million USD |
| marketcap.company | $72.70 Million USD |
| Reuters | $72.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more